相似文献
1
World Bronchiectasis Conference 2025-Inclusive Lungs, Diverse Solutions.
Respirology. 2025 Jul;30(7):552-554. doi: 10.1111/resp.70063. Epub 2025 May 21.
2
[Chinese expert consensus on diagnosis and treatment of non-tuberculous mycobacterial pulmonary disease complicated with bronchiectasis].
Zhonghua Jie He He Hu Xi Za Zhi. 2025 Feb 12;48(2):101-115. doi: 10.3760/cma.j.cn112147-20240808-00471.
3
Mice with lung airway ciliopathy develop persistent lung infection and have a proinflammatory lung phenotype associated with decreased T regulatory cells.
Front Immunol. 2022 Nov 25;13:1017540. doi: 10.3389/fimmu.2022.1017540. eCollection 2022.
4
Validity and Reliability of CAT and Dyspnea-12 in Bronchiectasis and Tuberculous Destroyed Lung.
Tuberc Respir Dis (Seoul). 2012 Jun;72(6):467-74. doi: 10.4046/trd.2012.72.6.467. Epub 2012 Jun 29.
5
[Radiology of bronchiectasis].
Radiologie (Heidelb). 2024 Nov;64(11):875-884. doi: 10.1007/s00117-024-01375-0. Epub 2024 Oct 15.
6
Azithromycin to prevent acute lower respiratory infections among Australian and New Zealand First Nations and Timorese children (PETAL trial): study protocol for a multicentre, international, double-blind, randomised controlled trial.
BMJ Open. 2025 Feb 5;15(2):e097455. doi: 10.1136/bmjopen-2024-097455.
7
Prevalence of non-bronchial systemic culprit arteries in patients with hemoptysis with bronchiectasis and chronic pulmonary infection who underwent de novo bronchial artery embolization.
Eur Radiol. 2023 Jun;33(6):4198-4204. doi: 10.1007/s00330-022-09310-4. Epub 2022 Dec 6.
8
Rapid microbial evaluation of acute exacerbations of bronchiectasis using FilmArray Pneumonia plus Panel in a real-world setting.
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251341751. doi: 10.1177/17534666251341751. Epub 2025 Jun 21.
9
Pathophysiology, causes and genetics of paediatric and adult bronchiectasis.
Respirology. 2019 Nov;24(11):1053-1062. doi: 10.1111/resp.13509. Epub 2019 Feb 25.
10
Paediatric and adult bronchiectasis: Monitoring, cross-infection, role of multidisciplinary teams and self-management plans.
Respirology. 2019 Feb;24(2):115-126. doi: 10.1111/resp.13451. Epub 2018 Nov 30.
本文引用的文献
1
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.
N Engl J Med. 2025 Apr 24;392(16):1569-1581. doi: 10.1056/NEJMoa2411664.
2
Efficacy and safety of long-term macrolide therapy for non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis.
Respir Investig. 2024 Nov;62(6):1079-1087. doi: 10.1016/j.resinv.2024.09.004. Epub 2024 Sep 25.
3
Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study.
Eur Respir J. 2025 Jan 2;65(1). doi: 10.1183/13993003.01551-2024. Print 2025 Jan.
4
World Bronchiectasis Day 2022.
Eur Respir J. 2022 Jun 30;59(6). doi: 10.1183/13993003.01249-2022. Print 2022 Jun.
5
De L'Auscultation Médiate; ou Traité du Diagnostic des Maladies des Poumons et du Cœur, fondé principalement sur ce Nouveau Moyen d'Exploration.
Edinb Med Surg J. 1822 Jul 1;18(72):447-474.
6
Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity.
Lancet. 2018 Sep 8;392(10150):880-890. doi: 10.1016/S0140-6736(18)31767-7.
7
Blood Neutrophils Are Reprogrammed in Bronchiectasis.
Am J Respir Crit Care Med. 2018 Oct 1;198(7):880-890. doi: 10.1164/rccm.201712-2423OC.
8
Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis.
Am J Respir Crit Care Med. 2012 Oct 1;186(7):657-65. doi: 10.1164/rccm.201203-0487OC. Epub 2012 Jun 28.
9
Reduction in bronchial subdivision in bronchiectasis.
Thorax. 1950 Sep;5(3):233-47. doi: 10.1136/thx.5.3.233.
10
A study of the pathology and pathogenesis of bronchiectasis.
Thorax. 1952 Sep;7(3):213-39. doi: 10.1136/thx.7.3.213.
Zotero 插件